Biotech Values

[genisi]

CRME
On vernakalant(i.v): There's a head-to-head phase III trial in Europe of vernakalant vs amiodarone for acute AF conversion. (http://clinicaltrials.gov/ct2/show/NCT00668759?term=AVRO&rank=1)
If vernakalant shows superior efficacy with adequate safety (I think it will), it will become the drug of choice for conversion of AF, and the European label might include HF patients.
Oral vernakalant likely will be safer but less effective than amiodarone, but will be interesting how it will compare to Multaq.